Operative delay predicts cancer return after cystectomy

Montreal, Quebec-The interval between transurethral resection of bladdertumor and radical cystectomy significantly influences 3-year disease recurrencerates in patients with transitional cell carcinoma of the bladder, saidresearchers from McGill University in Montreal.

Related Videos

Related Content

Advertisement

October 14th 2024

Phase 3 trial of 64Cu-SAR-bisPSMA in BCR of prostate cancer set to launch in 2025

Hannah Clarke

Patient recruitment for the phase 3 AMPLIFY trial is set to begin early next year.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

October 14th 2024

Lisa F. Newcomb, PhD, on active surveillance for prostate cancer

Lisa F. Newcomb, PhD

"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the risk-benefit of PSA screening," says Lisa F. Newcomb, PhD.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

October 11th 2024

Upper tract urothelial carcinoma: An in-depth review for urologists

Jesse Persily, MD Sameer Thakker, MD Katie S. Murray, DO, MS

"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.

October 11th 2024

Biomarker may predict MIBC status following neoadjuvant chemo

Elizabeth R. Plimack, MD, MS, FASCO

"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.

Related Content

Advertisement

October 14th 2024

Phase 3 trial of 64Cu-SAR-bisPSMA in BCR of prostate cancer set to launch in 2025

Hannah Clarke

Patient recruitment for the phase 3 AMPLIFY trial is set to begin early next year.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

October 14th 2024

Lisa F. Newcomb, PhD, on active surveillance for prostate cancer

Lisa F. Newcomb, PhD

"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the risk-benefit of PSA screening," says Lisa F. Newcomb, PhD.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

October 11th 2024

Upper tract urothelial carcinoma: An in-depth review for urologists

Jesse Persily, MD Sameer Thakker, MD Katie S. Murray, DO, MS

"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.

October 11th 2024

Biomarker may predict MIBC status following neoadjuvant chemo

Elizabeth R. Plimack, MD, MS, FASCO

"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.